Company Overview - NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [3] - The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [3] - DA-1726 is a novel oxyntomodulin (OXM) analogue acting as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), potentially leading to superior weight loss compared to selective GLP1R agonists [3] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in preclinical studies [3] Investor Engagement - NeuroBo Pharmaceuticals will participate in the Life Science Virtual Investor Forum on November 14, 2024, with presentations by CEO Hyung Heon Kim and CFO Marshall H. Woodworth [1] - The company will also present at the Winter 2024 Investor Summit Virtual on November 21, 2024, with the same management team [1] - Interested parties can register for the conferences to listen to presentations or schedule one-on-one meetings [1][2]
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November